In vivo efficacy and ultrastructural effects of mitomycin C against experimental alveolar hydatid disease.
The in vivo efficacy and ultrastructural effects of mitomycin C were determined against alveolar hydatid disease in experimentally infected animals and compared to mebendazole treatment. Mitomycin C inhibited the mean cyst mass of treated versus control animals by 84.1% which was statistically significant at the alpha = 0.01 level. Mebendazole given daily inhibited the mean cyst mass by 80.1%, while mebendazole administration on the same treatment schedule as that used for mitomycin C inhibited the mean cyst mass by 70.4%. Ultrastructurally, mitomycin C was not observed to affect the tegumental microtriches (microvilli) or the microtubular system. However, an increase in the number and accumulation of round to oval electrondense vesicles was observed within the subtegument. These inclusion bodies became vacuolated, subsequently degenerated, and formed myelin-like figures. Mitomycin C, like mebendazole, was only cystistatic in its effects on the cyst stage of Echinococcus multilocularis as evidenced by the growth of treated cyst material following inoculation into helminth-free animals.
D000818:Animals; D003411:Arvicolinae / Q000469:parasitology; D001835:Body Weight / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004443:Echinococcosis / Q000188:drug therapy* / Q000469:parasitology; D004446:Echinococcus / Q000187:drug effects* / Q000648:ultrastructure; D005260:Female; D008463:Mebendazole / Q000627:therapeutic use; D008854:Microscopy, Electron; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use*; D013997:Time Factors
D008937:Mitomycins; D016685:Mitomycin; D008463:Mebendazole